Anzeige
Mehr »
Login
Sonntag, 23.06.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Kursrakete startet...: Jetzt einsteigen und von außergewöhnlichem Potenzial profitieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JD8X | ISIN: US92243A2006 | Ticker-Symbol: NB11
Tradegate
21.06.24
21:47 Uhr
0,678 Euro
+0,003
+0,44 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
VAXART INC Chart 1 Jahr
5-Tage-Chart
VAXART INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,6400,68022.06.
0,6660,68121.06.

Aktuelle News zur VAXART Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiVaxart anticipates funds to extend its cash runway into 202617
MoVaxart Stock Is Moving Higher After The Bell: What's Going On?11
MoVaxart, Inc.: Vaxart Provides Business Update190- Cash runway extended into 2026 - - Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million - - Company well-capitalized to execute on multiple key clinical and...
► Artikel lesen
14.06.Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering12
14.06.Vaxart jumps 60% on $40M financing18
14.06.Vaxart Announces Underwritten Offering Of 50 Mln Shares At $0.80/shr9
14.06.Vaxart, Inc.: Vaxart Announces $40 Million Underwritten Offering of Common Stock13
13.06.Vaxart soars after hours on $453M award to evaluate COVID-19 oral pill vaccine candidate13
13.06.Vaxart, Inc.: Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate90- 10,000-subject Phase 2b study will evaluate Vaxart's next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator - - Vaxart anticipates initiating enrollment as early...
► Artikel lesen
13.06.Vaxart, Inc. - 8-K, Current Report8
23.05.Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)82SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on May 17, 2024, the Compensation Committee of the Board...
► Artikel lesen
14.05.Vaxart, Inc. (NASDAQ:VXRT) Q1 2024 Earnings Call Transcript7
14.05.Earnings call: Vaxart posts progress in vaccine trials, Q1 financials9
13.05.Vaxart Inc reports results for the quarter ended in March - Earnings Summary4
13.05.Vaxart up 10% on quarterly revenue beat, eyes COVID oral vaccine trial start in Q23
13.05.Vaxart Stock Climbs After Blockbuster Q1 Revenue6
13.05.Vaxart, Inc. - 10-Q, Quarterly Report1
13.05.Vaxart, Inc.: Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results109Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart's oral pill vaccine candidate to protect or reduce the effect of the disease in infants Expects...
► Artikel lesen
30.04.Vaxart, Inc. - 8-K, Current Report2
30.04.Vaxart, Inc.: Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers208Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through passive antibody transfer SOUTH SAN FRANCISCO, Calif., April 30, 2024...
► Artikel lesen
Seite:  Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
4,1,1